Reproductive BioMedicine Online
Volume 20, Issue 2 , Pages 175-181 , February 2010

Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support

Received 28 January 2009 ,Revised 31 March 2009 ,Accepted 11 November 2009.

References 

  1. Acevedo B, Gomez-Palomares JL, Ricciarelli E, et al. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil. Steril. 2006;86:1682–1687
  2. Albano C, Smitz J, Camus M, et al. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil. Steril. 1997;67:917–922
  3. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod. Biomed. Online. 2007;14:640–649
  4. Babayof R, Margalioth EJ, Huleihel M, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum. Reprod. 2006;21:1260–1265
  5. Balasch J, Fábregues F, Tur R, et al. Further characterization of the luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Hum. Reprod. 1995;10:1377–1381
  6. Binder H, Dittrich R, Einhaus F, et al. Update on ovarian hyperstimulation syndrome: part 1 – incidence and pathogenesis. Int. J. Fertil. Womens Med. 2007;52:11–26
  7. Bodri, D., Guillén, J.J., Galindo, A., et al., 2008. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil. Steril. [Epub ahead of print].
  8. Bracero, N.J., Jurema, M.W., Posada, M.N., 2001. Triggering ovulation with leuprolide acetate (LA) instead of human chorionic gonadotrophin (hCG) after the use of ganirelix for in-vitro fertilization-embryo transfer (IVF−ET) does not compromise cycle outcome and may prevent ovarian hyperstimulation syndrome. Fertil. Steril. (Suppl.) S93 (O-254).
  9. Casañ EM, Raga F, Bonilla-Musoles F, et al. Human oviductal gonadotropin-releasing hormone: possible implications in fertilization, early embryonic development, and implantation. J. Clin. Endocrinol. Metab. 2000;85:1377–1381
  10. Dhont M, Van der Straeten F, De Sutter P. Prevention of severe ovarian hyperstimulation by coasting. Fertil. Steril. 1998;70:847–850
  11. Diedrich K, Diedrich C, Santos E, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum. Reprod. 1994;9:788–791
  12. Emperaire JC, Parneix I, Ruffie A. Luteal phase defects following agonist-triggered ovulation: a patient-dependent response. Reprod. Biomed. Online. 2004;9:22–27
  13. Engmann L, DiLuigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in-vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil. Steril. 2008;89:84–91
  14. Engmann L, Siano L, Schmidt D, et al. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod. Biomed. Online. 2006;13:639–644
  15. Golan A, Ron-el R, Herman A, et al. Ovarian hyperstimulation syndrome: an update review. Obstet. Gynecol. Surv. 1989;44:430–440
  16. Gonen Y, Balakier H, Powell W, et al. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in-vitro fertilization. J. Clin. Endocrinol. Metab. 1990;71:918–922
  17. Griesinger G, Diedrich K, Tarlatzis BC, et al. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod. Biomed. Online. 2006;13:628–638
  18. Griesinger G, Kolibianakis EM, Papanikolaou EG, et al. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonista or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertil. Steril. 2007;88:616–621
  19. Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: a reevaluation. J. Clin. Endocrinol. Metab. 1983;57:792–796
  20. Hugues JN. Ovarian stimulation for assisted reproductive technologies. In:  Vayena E,  Rowe PJ,  Griffin PD editor. Current Practices and Controversies in Assisted Reproduction. Geneva, Switzerland: World Health Organization; 2002;p. 102–125
  21. Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum. Reprod. 2005;20:1213–1220
  22. Humaidan P, Bungum L, Bungum M, et al. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod. Biomed. Online. 2006;13:173–178
  23. Imoedemhe DA, Sigue AB, Pacpaco EL, et al. Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in-vitro fertilization. Fertil. Steril. 1991;55:328–332
  24. Itskovitz J, Boldes R, Levron J, et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil. Steril. 1991;56:213–220
  25. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum. Reprod. 2000;15:1965–1968
  26. Kol S. Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent!. Hum. Reprod. 2003;18:1557–1558
  27. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil. Steril. 2004;81:1–5
  28. Kol S, Muchtar M. Recombinant gonadotrophin-based, ovarian hyperstimulation syndrome-free stimulation of the high responder: suggested protocol for further research. Reprod. Biomed. Online. 2005;10:575–577
  29. Kolibianakis EM, Schultze-Mosgau A, Schroer A, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum. Reprod. 2005;20:2887–2892
  30. Latouche J, Crumeyrolle-Arias M, Jordan D, et al. GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology. 1989;125:1739–1741
  31. Macklon NS, Stouffer RL, Giudice LC, et al. The science behind 25 years of ovarian stimulation for in-vitro fertilization. Endocr. Rev. 2006;27:170–207
  32. Minaretzis D, Jakubowski M, Mortola JF, et al. Gonadotrophin releasing hormone receptor gene expression in human ovary and granulosa lutein cells. J. Clin. Endocrinol. Metab. 1995;80:430–434
  33. Nakano R, Mizuno T, Kotsuji F, et al. ‘Triggering’ of ovulation after infusion of synthetic luteinizing hormone releasing factor (LRF). Acta Obstet. Gynecol. Scand. 1973;52:269–272
  34. Orvieto R. Can we eliminate severe ovarian hyperstimulation syndrome?. Hum. Reprod. 2005;20:320–322
  35. Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in-vitro fertilization cycles. Fertil. Steril. 2006;85:112–120
  36. Parneix I, Emperaire JC, Ruffie A, et al. Comparison of different protocols of ovulation induction, by GnRH agonists and chorionic gonadotropin. Gynécol. Obstét. Fertil. 2001;29:100–105
  37. Peñarrubia J, Balasch J, Fábregues F, et al. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Hum. Reprod. 1998;13:3315–3318
  38. Revel A, Casper RF. The use of LHRH agonists to induce ovulation. Infertil. Reprod. Med. Clin. North Am. 2001;12:105–118
  39. Rizk B. Epidemiology of ovarian hyperstimulation syndrome. In:  Rizk B editors. Ovarian Hyperstimulation Syndrome. Cambridge University Press; 2006;p. 10–42(Chapter 2)
  40. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Hum. Reprod. 1992;7:320–327
  41. Romeu A, Monzó A, Peiró T, et al. Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles. J. Assist. Reprod. Genet. 1997;14:518–524
  42. Segal S, Casper RF. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in-vitro fertilization. Fertil. Steril. 1992;57:1254–1258
  43. Shapiro BS, Daneshmand ST, Garner FC, et al. Gonadotropin-releasing hormone agonis combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in-vitro fertilization. Fertil. Steril. 2008;90:231–233
  44. Sharara FI, McClamrock HD. Ratio of oestradiol concentration on the day of human chorionic gonadotrophin administration to mid-luteal oestradiol concentration is predictive of in-vitro fertilization outcome. Hum. Reprod. 1999;14:2777–2782
  45. Takekida S, Deguchi J, Samoto T, et al. Comparative analysis of the effects of gonadotropin-releasing hormone agonist on the proliferative activity, apoptosis, and steroidogenesis in cultured porcine granulosa cells at varying stages of follicular growth. Endocr. 2000;12:61–67
  46. Veeck LL. The Morphological Assessment of Human Oocytes and Early Concepts. Handbook of the Laboratory Diagnosis and Treatment of Infertility. Boca Raton, FL: CRC Press; 1990;pp. 353–369

 Juan Carlos Castillo obtained his MD degree in 1998 and his speciality degree in Obstetrics and Gynaecology in 2005 at the Grau Emergency Hospital, Lima, Perú. In 2006, he received his Master’s degree in Human Reproduction from the Universidad de Valencia, Spain. Since then he has been working as a consultant specialist in reproductive medicine at Hospital Clínico Universitario de Valencia, Spain. His PhD thesis at Universidad de Valencia is focused on the prevention of ovarian hyperstimulation syndrome and will be defended in late 2009.

PII: S1472-6483(09)00231-4

doi: 10.1016/j.rbmo.2009.11.018

Reproductive BioMedicine Online
Volume 20, Issue 2 , Pages 175-181 , February 2010

Article Tools

* Image Usage & Resolution